Estudios originales
Published on 21 de julio de 2025 | http://doi.org/10.5867/medwave.2025.06.3002
Thrombotic thrombocytopenic purpura: Description and analysis of 23 cases treated in Chile between 2017 and 2022
| 33 | F | 0 | Respiratory/gastrointestinal | 7.2 | 7000 | 0.99 | 1279 | Yes | 6 | 9 | GC + PEX + RTX | |
| 40 | F | 3 | Gastrointestinal/neurologic | 5.4 | 21 000 | 1.3 | 763 | Yes | 4 | 6 | GC | |
| 40 | F | 0 | Hemorrhagic/cutaneous | 8.6 | 10 000 | 0.63 | 617 | Yes | 7 | 10 | GC + PEX + RTX | |
| 72 | F | 4 | Neurological | 9 | 9000 | 0.72 | 382 | Yes | 6 | 7 | GC + PEX + RTX | |
| 71 | F | 5 | Gastrointestinal/neurologic | 8.1 | 47 000 | 2.23 | 1479 | Yes | 5 | 6 | GC + PEX + RTX | |
| 89 | M | 10 | Neurological | 5.1 | 113 000 | 1.71 | 324 | No | 4 | 6 | GC | |
| 70 | M | 5 | Gastrointestinal/cutaneous | 4.5 | 82 000 | 0.92 | 384 | Yes | 4 | 9 | GC | |
| 68 | M | 6 | Neurological/fatigue | 8.2 | 18 000 | 6.21 | 1413 | No | 3 | 6 | GC + PEX | |
| 79 | F | 6 | Hemodynamic/respiratory/neurologic | 5.2 | 39 000 | 1.72 | 4908 | Yes | 5 | 7 | GC + PEX | |
| 77 | F | 9 | Respiratory/neurological | 6.3 | 27 000 | 4.5 | 293 | Yes | 5 | 5 | GC + PEX + RTX | |
| 78 | F | 9 | Fever/neurological | 8.2 | 10 000 | 1.38 | 250 | Yes | 4 | 8 | GC | |
| 27 | M | 0 | Gastrointestinal/cutaneous | 8.9 | 6000 | 0.91 | 1112 | Yes | 5 | 10 | GC | |
| 35 | F | 4 | Gastrointestinal/cutaneous | 11.2 | 140 000 | 0.85 | 537 | Yes | 6 | 6 | GC + PEX + RTX | |
| 85 | F | 5 | Gastrointestinal/neurologic | 8.7 | 17 000 | 1.3 | 164 | Yes | 5 | 6 | GC + PEX | |
| 61 | M | 2 | Fever/weight loss | 7.9 | 36 000 | 0.77 | 787 | Yes | 6 | 6 | GC | |
| 62 | F | 6 | Respiratory/haemorrhagic/neurological | 10.2 | 18 000 | 2.87 | 240 | No | 5 | 9 | GC | |
| 32 | F | 3 | Gastrointestinal | 6 | 6000 | 2.31 | 413 | Yes | 6 | 9 | GC + PEX + RTX | |
| 38 | M | 0 | Hemodynamic/respiratory | 9.4 | 32 000 | 2.32 | 908 | Yes | 5 | 6 | GC + PEX + RTX | |
| 88 | F | 10 | Respiratory/gastrointestinal/neurologic | 6.2 | 18 000 | 1.34 | 1145 | No | 5 | 7 | PEX + RTX | |
| 74 | F | 10 | neurological | 7.9 | 93 000 | 2.24 | 223 | No | 3 | 10 | Ninguno | |
| 41 | F | 0 | Hemorrhagic/hemodynamic | 6.9 | 7000 | 4.43 | 575 | Yes | 5 | 7 | GC + PEX | |
| 26 | F | 3 | Hemorrhagic | 6.7 | 184 000 | 4.79 | 645 | Yes | 3 | 4 | GC + PEX | |
| 52 | M | 1 | Respiratory | 5.8 | 605 | 4.26 | 3716 | Yes | 5 | 10 | Ninguno |
F, female; GC, glucocorticoid; LDH, lactate dehydrogenase. M, male. PEX, plasma exchange. PTT, thrombotic thrombocytopenic purpura. RTX, rituximab.2 PLASMIC score, 0 to 4 low risk; 5 intermediate risk; 6 to 7 high risk [20].
¹ Hemolysis defined by the presence of reticulocytes greater than 2,5%, undetectable haptoglobin or indirect bilirubin greater than 2, according to the definition provided by Bendapudi et al. in the creation of the PLASMIC score [20].
² PLASMIC SCORE 0 to 4 low risk; 5 intermediate risk; 6 to 7 high risk [20].
Source: Prepared by the authors of this study.